Agentiq's Reg A+ Bet on Ronny Cruz: Why the Fee Stack Beats the Odds

TL;DR: Agentiq wants you to buy a piece of a 20-year-old minor-league infielder's future paycheck. Ronny Cruz signed the deal in June 2026, the first athlete on the platform, giving up 10% of his future on-field baseball earnings for up to $1.2 million now. But layer in Agentiq's 4% negotiation fee, its 2.5% annual maintenance fee, and Andes Capital's 1% broker fee, and Sportico reports investors need Cruz to earn more than $13 million in career salary just to break even. Agentiq's own cited research says only about 45% of MLB's top-100 prospects who reach the majors ever earn that much. I would not buy this deal, and I want you to understand exactly why before anyone shows you the pitch deck.

What You're Actually Buying

You are not buying a stock. You are not buying a bond. You are buying a Unit in Agentiq Sports 1 Series LLC, a special-purpose vehicle registered with the SEC under Regulation A+ Tier II, the JOBS Act rule that lets companies raise up to $75 million a year from retail investors without a full IPO-style registration. The offering caps at $1,290,000, split into 12,900 Units priced at $100 each, according to the Form 1-A offering circular Agentiq filed with the SEC on June 15, 2026. It is a best-efforts raise. Nobody guarantees the full amount gets sold.

Here is the mechanism. Agentiq, co-founded by Zach Kurtz and Reuben Abraham, pays Ronny Cruz, a Washington Nationals farmhand playing for the Wilmington Blue Rocks, up to $1.2 million total, with $350,000 delivered upfront. In exchange, Cruz assigns up to 10% of his future on-field baseball earnings to the SPV. Investors who buy Units are buying a claim on that 10% income stream. If Cruz never reaches the majors, or reaches them and gets released after two years on a rookie minimum, the income stream is close to zero. There is no floor. There is no guaranteed coupon. This is not a bond dressed up as a novelty. It's a wager on one specific 20-year-old's body holding up and his bat catching up to big-league pitching.

Agentiq calls the paperwork a "Brand Advisory Agreement." Don't let the label fool you. The Form 1-A discloses that the advisory services shrink pro rata if the raise comes in under the $1,290,000 target. Real advisory contracts don't work that way. A marketing consultant doesn't do less consulting because your capital raise fell short. This is a legal wrapper around an income-share agreement, structured this way because outright securitizing a person's future earnings without the wrapper raises its own regulatory and public-relations problems. Call it what it is: a human-capital derivative with a nicer name on the label.

The Fee Stack, Line by Line

This is where I want you to slow down, because the fee stack is the whole story. Every dollar you commit passes through three separate tolls before it does anything for you as an investor.

Fee	Rate	Approx. Dollar Amount	Who Collects It
Negotiation fee	4% of raise	~$50,000	Agentiq
Annual maintenance fee	2.5% of raise, per year	~$32,250/year	Agentiq
Broker-dealer fee	1% of gross proceeds	~$12,900	Andes Capital

Run the math with me. On a full $1,290,000 raise, Agentiq pockets roughly $50,000 up front just for negotiating the deal, then bills investors another $32,250 every single year the fund exists, whether Cruz is hitting .280 in Double-A or sitting on a rookie-ball injured list. Andes Capital, the FINRA-registered broker-dealer running the offering, takes its 1% cut off the top regardless of outcome. None of these three fees are contingent on Cruz's success. They get paid whether the bet wins or loses. You, the Unit holder, only get paid if Cruz's career earnings clear a bar high enough to cover his $1.2 million payout, Agentiq's cumulative fees compounding year over year, and Andes' commission, and then leave a positive return on top of all of it.

Sportico's reporting puts the true break-even point at north of $13 million in career MLB salary for Cruz. That's not $13 million in a signing bonus. That's cumulative career pay across a body of work that includes years at the minimum. For context, the current MLB minimum salary sits in the $780,000 range under the league's collective bargaining agreement, so simply making a big-league roster does almost nothing for you. Cruz needs multiple productive years, ideally a long-term extension or arbitration payouts, to get anywhere near that $13 million threshold.

And here's the detail that should stop you cold: Agentiq's own offering document, the one it filed with the SEC, states that roughly 45% of MLB's top-100 prospects who actually reach the majors go on to earn somewhere between $3 million and $15 million in career pay. Cruz is not currently ranked as a top-100 prospect. He is a mid-level Nationals system player. The company underwriting your break-even case is using a reference class more talented than the athlete you're actually investing in, and even that more talented reference class clusters below your break-even line nearly half the time.

Verification Over Optimism: What the Filing Actually Says

I built my career on one rule: verify before you believe the pitch. So I read the filing, not just the press coverage. The EDGAR filing index for Agentiq Sports 1 Series LLC, CIK 0002105654, confirms this is a brand-new entity with no operating history. Agentiq itself qualifies as an "emerging growth company" under the JOBS Act, a designation that comes with reduced disclosure obligations, not more. There is no public trading market for these Units. None exists. None is promised. If you want out before Cruz's career resolves one way or the other, you're stuck. There's no exchange, no bulletin board, no secondary market maker standing by. Your capital is locked until either Cruz's playing career ends or Agentiq engineers some future liquidity event it hasn't specified.

Reg A+ was designed to democratize access to early-stage deals that used to be reserved for accredited investors. That's a genuinely good idea when the underlying asset is a business with revenue, customers, and a repeatable model. Agentiq is applying that regulatory tool to a single human body's future paycheck. Different risk category entirely. A startup can pivot. A minor leaguer with a torn UCL cannot pivot his way around Tommy John surgery and two years of rehab.

The Precedent Nobody at the Pitch Meeting Wants to Discuss

This isn't the first time someone tried to turn athlete paychecks into a retail security. It's the third.

Fantex tried it first, back in the 2010s, selling tracking stocks tied to the brand income of NFL players like Vernon Davis and, later, international interest around stars such as Neymar. The pitch sounded identical to Agentiq's: buy a fractional interest in an athlete's future earning power, let the platform handle the structuring. Fantex never built a durable secondary market for those tracking stocks and eventually wound the offerings down. Retail investors who bought in were left holding an illiquid interest in a company that had moved on.

Big League Advance (BLA) took a different structural approach. Instead of one retail offering per athlete, BLA bought future-earnings shares directly from dozens of minor leaguers in exchange for lump-sum cash, spreading its bet across a portfolio the way a venture fund spreads bets across a startup portfolio. Pooling risk across many prospects is exactly what made BLA's model defensible in a way a single-name Reg A+ offering isn't. But BLA also generated real controversy. Fernando Tatis Jr., one of BLA's earliest and most successful signings, challenged the terms of his agreement once he inked a $340 million extension with the San Diego Padres. Tatis took the dispute to arbitration over how much of that extension BLA was entitled to claim, and the case became a cautionary tale about what happens when an athlete's success outpaces the contract he signed as a broke teenager. BLA won that specific fight, according to Sportico's reporting on the history of athlete-earnings securitization, but the reputational damage to the "buy a piece of a prospect" pitch stuck around.

Agentiq is now asking retail investors, not venture funds with diversified portfolios of dozens of prospects, to take a concentrated, single-name bet on one player, with a fee stack layered on top that neither Fantex nor BLA's original structure carried in the same form. Where BLA at least pooled risk across a large roster of prospects, an individual Reg A+ offering like this one gives you exposure to exactly one outcome: Ronny Cruz's bat, his health, and his next six years of assignments through the minor-league system.

Newer platforms in this space, including Defy, Vestible, and Finlete, are running variations on the same basic idea: securitize an athlete's brand or earnings, sell fractional access to retail. None of them yet have a track record of paying out a full cycle of investor returns on a completed athlete career. You would be an early cohort in an unproven category, for the third time in a decade that category has been tried.

The Honest Caveat

I'll give the other side its due. Reg A+ offerings do force real disclosure. Agentiq filed a public document with specific numbers, not a vague pitch deck. That's more transparency than most alternative-asset hype gets, and I respect that the fee structure is written down in black and white rather than buried in fine print you'd need a subpoena to find. If you read the filing carefully, as I did, you know exactly what you're signing up for. That's the system working as designed.

It's also true that a small allocation, money you can genuinely afford to lose entirely, buys you a real story and a real, if thin, shot at outsized return if Cruz breaks out. Some investors want that lottery ticket with eyes open. I'm not telling you the deal is fraudulent. I'm telling you the expected value math, once you include the fee stack and the base rate for prospects reaching Cruz's tier, skews hard against the retail buyer.

What I'd Actually Do

If you're tempted by this deal or the next one like it, do three things before you wire a dollar.

• Pull the actual Form 1-A from EDGAR and read the risk factors section yourself. Don't rely on a summary, mine included.
• Calculate your personal break-even, not the company's. Include every fee, compounded across your expected holding period, not just year one.
• Size the position as a total-loss bet. If a $500 or $1,000 allocation wouldn't sting if it went to zero, and you understand there's no exit before Cruz's career resolves, that's the only way I'd touch this category.

Athlete income-share deals aren't inherently a scam. They're a legitimate, high-variance asset class with a rough track record so far, Fantex closed, BLA fought its own star client in arbitration, and now Agentiq is asking you to underwrite career-ending injury risk on a single unproven prospect while collecting fees whether he ever gets there or not. Verification over optimism. Read the filing. Do the break-even math yourself. Then decide if $13 million in career salary is a bet you actually believe in, or just a story you liked.

Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.